GlassScriptPhysician profile
Dalia Frasca
NPI 1255917415
$12,513.19
in general payments reported to CMS, 2019-2025
43 companies · $5,172 in 2025
The $5,172 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,384 · 2022: $1,157 · 2023: $2,494 · 2024: $2,306 · 2025: $5,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,566 · Travel and Lodging: $1,199 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,565.63 |
| Travel and Lodging | $1,199.22 |
| Education | $207.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,689.90 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,588.48 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,102.18 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $934.55 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $612.12 | 2023-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $543.99 | 2022-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $488.37 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $487.17 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.95 | 2021-2025 | Ofev, Spiriva Respimat, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $460.21 | 2021-2025 | Glassia, Hyqvia |
| Amgen INC. | $431.46 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $427.61 | 2021-2025 | Winrevair, Zerbaxa, Keytruda |
| Actelion Pharmaceuticals US, INC. | $422.71 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Paratek Pharmaceuticals, INC. | $310.60 | 2021-2024 | Nuzyra |
| Avadel Cns Pharmaceuticals, LLC | $217.82 | 2023-2025 | Lumryz |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $215.23 | 2021-2024 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $214.20 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $201.91 | 2023-2025 | Xolair |
| Mylan Specialty L.P. | $192.25 | 2021-2023 | Yupelri |
| Philips North America LLC | $133.85 | 2023-2025 | Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $120.11 | 2021-2024 | |
| Harmony Biosciences LLC | $112.81 | 2025 | |
| Electromed, INC. | $112.08 | 2021-2025 | Smartvest |
| Insmed, INC. | $107.61 | 2021-2025 | Arikayce, Brinsupri |
| Pharming Healthcare, INC. | $100.07 | 2022-2024 | Ruconest |
| Baxter Healthcare | $93.78 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $81.20 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $70.53 | 2021-2024 | Xarelto |
| Verona Pharma, INC. | $62.59 | 2025 | Ohtuvayre |
| Shionogi INC | $53.25 | 2024 | Fetroja |
| Teva Pharmaceuticals USA, INC. | $49.79 | 2021-2022 | |
| Vifor Pharma, INC. | $49.05 | 2024 | Zemaira |
| Pfizer INC. | $45.21 | 2021-2022 | |
| Lilly USA, LLC | $43.16 | 2025 | Zepbound |
| Advanced Respiratory, INC | $40.03 | 2021 | |
| Breas Medical, INC. | $36.29 | 2024 | Vivo 45 Ls |
| Viatris Specialty LLC | $36.04 | 2025 | Yupelri |
| 3b Medical, INC. | $34.71 | 2025 | Luna |
| Abbvie INC. | $33.17 | 2024-2025 | |
| United Therapeutics Corporation | $22.52 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.12 | 2023 | Quviviq |
| Resmed Corp | $19.82 | 2024 | |
| La Jolla Pharmaceutical Company | $17.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalia Frasca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.